Drug Discovery World

JULY 5, 2023

MG: I am responsible for Agilent’s cancer segment. A fulfilling part of my job is meeting the scientists, companies, and institutions at the forefront of ground-breaking research that are advancing patient health outcomes. Mark Garner, PhD., RA: Please can you tell us a bit more about your role at Agilent?

Research 98

Research Protein Scientist Immune Response 98

Drug Discovery World

JULY 22, 2022

By Courtney Ferrebee, PhD, Field Applications Scientist, Taconic Biosciences. As a result, researchers are striving to continually improve immuno-oncology approaches using the patient’s own immune cells to combat tumours. However, adverse effects such as cytokine release syndrome (CRS) and neurotoxicity still occur.

In-Vivo 52

In-Vivo Engineer In-Vitro Antibody 52

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Protein 57

Protein Antibody Engineer Scientist 57

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody 62

Antibody Engineer Protein Scientist 62